- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01238445
Assessing Response to Albuterol in Bronchiolitis
31. januar 2017 opdateret af: Christopher Carroll, MD, Connecticut Children's Medical Center
Bronchiolitis is a significant cause of morbidity and hospitalizations in children, accounting for more than 125,000 hospitalized children per year in the United States.
Although treatment is largely supportive, bronchodilator medications such as albuterol are frequently used due to increased pulmonary resistance in this population.2-4
However, despite four decades of clinical trials, the efficacy of albuterol in the treatment of bronchiolitis has yet to be proven.
This inconsistency is due in part to the lack of sufficiently sensitive methods for the evaluation of lung function and thus the response to albuterol in infants.
Because of the difficulties in evaluating the response to therapy, healthcare providers are forced to rely on their physical examination skills or a clinical scoring system, both of which are highly subjective in this population.
The investigators propose to conduct a prospective observational study of healthcare providers to determine the accuracy of clinical assessment as compared to that of pulmonary mechanics in a population of children intubated and mechanically ventilated for bronchiolitis.
Studieoversigt
Status
Afsluttet
Betingelser
Detaljeret beskrivelse
We propose to conduct a prospective observational study of healthcare providers to determine the accuracy of clinical assessment as compared to the assessment of pulmonary mechanics in a population of children intubated and mechanically ventilated for bronchiolitis.
Before and at 20 minutes following a routinely scheduled albuterol treatment, measurements of pulmonary mechanics obtained as part of the child's clinical care will be compared to a healthcare provider's simultaneous clinical assessment.
Three healthcare providers (a nurse, physician, and respiratory therapist) will assess the child during these time periods.
Data regarding their observations will be recorded using a data collection tool (attached).
Healthcare providers will be blinded to each other's assessments and to the measurements of pulmonary mechanics.
Using sensitivity and specificity analysis, the healthcare provider's assessment of response will be compared to the standard assessment of response according to the measurements of pulmonary mechanics.
A precision of the estimate of sensitivity and specificity will be calculated.
Clinical characteristics of the child will be recorded.
Each child may be assessed on up to three occasions if that child receives greater than 1 dose of albuterol.
However, no more than 3 providers will assess the child at one time.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
29
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06106
- Connecticut Children's Medical Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
Ikke ældre end 2 år (Barn)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Sandsynlighedsprøve
Studiebefolkning
Children hospitalized in the intensive care unit with bronchiolitis
Beskrivelse
Inclusion Criteria:
- Hospitalization with a primary admission diagnosis of bronchiolitis
- Age between birth and 2 years
- Intubated with < 1 cm H2O leak around endotracheal tube
- Receiving inhaled albuterol therapy
Exclusion Criteria:
- Not meeting inclusion criteria
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Our primary outcome is the response to albuterol.
Tidsramme: 20 minutes following an albuterol treatment
|
20 minutes following an albuterol treatment
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Christopher L Carroll, MD, MS, Connecticut Children's Medical Center
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. november 2010
Primær færdiggørelse (Faktiske)
1. november 2016
Studieafslutning (Faktiske)
1. november 2016
Datoer for studieregistrering
Først indsendt
8. november 2010
Først indsendt, der opfyldte QC-kriterier
9. november 2010
Først opslået (Skøn)
10. november 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
2. februar 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
31. januar 2017
Sidst verificeret
1. januar 2017
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 10-095
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Bronchiolitis
-
Regend TherapeuticsShanghai Children's HospitalRekrutteringPædiatrisk Bronchiolitis ObliteransKina
-
Fondazione IRCCS Policlinico San Matteo di PaviaAfsluttetBronchiolitis Obliterans Syndrom (BOS)Italien
-
Hillel Yaffe Medical CenterAfsluttetZoneterapi | Bronchiolitis; KemiskIsrael
-
National Heart, Lung, and Blood Institute (NHLBI)AfsluttetBronchiolitis Obliterans | Graft vs værtssygdom | Konstriktiv bronchiolitis | Bronchiolitis, exudativ | Bronchiolitis, proliferativForenede Stater
-
NYU Langone HealthAfsluttetAkut bronchiolitisForenede Stater
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinAfsluttetAlvorlig viral bronchiolitisFrankrig
-
Hospices Civils de LyonAfsluttet
-
Guy's and St Thomas' NHS Foundation TrustAfsluttetAkut viral bronchiolitisDet Forenede Kongerige
-
Assistance Publique - Hôpitaux de ParisAfsluttetAkut viral bronchiolitisFrankrig
-
Ministry of Health, SpainAfsluttet